New Jersey 2024-2025 Regular Session

New Jersey Assembly Bill A4023

Introduced
3/7/24  

Caption

Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

Impact

The bill mandates the creation and maintenance of a prioritization list of prescription drugs, devices, and biological products for bulk purchasing initiatives. This list will help focus state efforts on high-cost items that represent significant expenditures. The prioritization criteria include the drug's price, availability of alternatives, and past purchase costs to the State, aiming to enhance financial efficiency in healthcare spending across state programs and agencies. Furthermore, local governments and private purchasers will have the opportunity to benefit from these arrangements, promoting broader access to essential healthcare products.

Summary

Assembly Bill A4023 aims to establish requirements for State entities in New Jersey to enter into bulk purchasing arrangements for pharmaceutical products. The bill is designed to maximize the State's bargaining power with regard to the procurement of pharmaceuticals and pharmacy services, thereby reducing costs associated with purchasing these essential products. The Director of the Division of Purchase and Property in the Department of Treasury will oversee this initiative, reviewing all current contracts and arrangements to identify opportunities for cost savings through collective purchasing efforts.

Contention

Notable points of contention surrounding A4023 may arise from concerns about the implications for competition in the pharmaceutical market and potential pushback from drug manufacturers. Supporters argue that consolidating purchasing power can lower costs and enhance access to medications, particularly for state-run programs. Critics, however, may contend that such measures could undermine market dynamics and innovation or pose challenges for smaller suppliers who might struggle to compete in a bulk purchasing framework. Transparency in the prioritization process and ongoing evaluations of the program's effectiveness will be needed to address these concerns.

Companion Bills

NJ S1396

Same As Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

NJ S781

Carry Over Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

Similar Bills

NJ S1396

Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

NJ S781

Establishes requirements for State entities to enter into bulk purchasing arrangements for pharmaceutical products.

CA AB6

Local ballot measures: statement of the measure.

CT SB01202

An Act Concerning Prescription Drug Affordability.

TX HB4990

Relating to the Texas Pharmaceutical Initiative and a governing board and advisory council for the initiative.

MS SB2012

Mississippi Health Care Cost Transparency Act; enact.

CT HB06669

An Act Protecting Patients And Prohibiting Unnecessary Health Care Costs.

CT HB05384

An Act Concerning Prescription Drug Costs.